 |
 |

Effects of Topical Anti-inflammatory and Antiallergic Eyedrops on Prostaglandin E2Induced Aqueous Flare Elevation in Pigmented Rabbits
Yoriko Hayasaka, MD;
Seiji Hayasaka, MD;
Xue-Yun Zhang, PhD;
Yasunori Nagaki, MD
Arch Ophthalmol. 2002;120:950-953.
ABSTRACT
 |  |
Objective To evaluate the role of topical instillation of anti-inflammatory or
antiallergic agents on experimental elevation of aqueous flare induced by
prostaglandin E2 (PGE2) in pigmented rabbits.
Methods Transcorneal diffusion of PGE2, 25 µg/mL (7.09 x
10 -2mmol/L), by means of a glass cylinder produced aqueous
flare elevation. Anti-inflammatory or antiallergic agents were topically administered
once or twice before PGE2 application. Aqueous flare was measured
with a laser flare-cell meter. Results are given as mean ± SD.
Results Double instillations of 0.1% betamethasone sodium phosphate and 0.1%
fluorometholone acetate at 4 and 2 hours before PGE2 application
inhibited 61% ± 11% and 46% ± 14%, respectively, of flare elevation.
Double instillations of 0.1% diclofenac sodium and 0.1% pranoprofen at 4 and
2 hours before PGE2 application did not inhibit flare elevation.
Double instillations of 0.1% betamethasone, 0.1% fluorometholone, 0.1% diclofenac,
and 0.1% pranoprofen at 1 and 0.5 hour before PGE2 application
inhibited 16% ± 10%, 16% ± 6%, 24% ± 9%, and 23% ±
10%, respectively, of flare elevation. Double instillations of 2% cromolyn
sodium, 0.5% tranilast, 0.025% levocabastine hydrochloride, 0.1% pemirolast
potassium, and 0.01% ibudilast at 1 and 0.5 hour before PGE2 application
did not inhibit flare elevation. Single instillation of 0.1% betamethasone
6 hours before PGE2 application inhibited 88% of PGE2-induced
aqueous flare elevation. Single instillation of 0.1% diclofenac 1 hour before
PGE2 application inhibited 23% of PGE2-induced aqueous
flare elevation.
Conclusions Betamethasone needed several hours after topical instillation to inhibit
flare elevation, but diclofenac needed 1 hour. Antiallergic agents did not
affect disruption of the blood-aqueous barrier in rabbits.
Clinical Relevance Corticosteroid eyedrops may need several hours from instillation to
show action.
INTRODUCTION
PREVIOUS STUDIES from our laboratory have shown that transcorneal diffusion
of prostaglandin E2 (PGE2) by means of a glass cylinder
induced aqueous flare elevation in pigmented rabbits, and that the elevation
was reproducible when PGE2 was applied at an interval of more than
1 week.1-2 We also found that
topical instillation of 0.25% clonidine hydrochloride, 0.5% betaxolol hydrochloride,
1.15% apraclonidine hydrochloride, 1.25% epinephrine bitartrate, or 0.04%
dipivefrin hydrochloride inhibited flare elevation in rabbits.3-5
Elevation of aqueous flare after cataract surgery was inhibited by anti-inflammatory
agents. Othenin-Girard et al6 reported that
diclofenac sodium seemed to be as effective as dexamethasone sodium phosphate.
Miyake et al7 reported that the amount of flare
after cataract surgery was lower in a diclofenac group than that in a fluorometholone
group. Mast cells contain many small granules of substances that mediate inflammation.
Histamine produces the itching and redness.8
In the present study, therefore, we evaluated the effects of anti-inflammatory
or antiallergic agents on PGE2-induced aqueous flare elevation
in pigmented rabbits.
Corticosteroids bind to a specific receptor and enter into the cytoplasm
and nucleus, which leads to the synthesis of specific proteins.9
Dexamethasone decreased a 4-kilobase messenger RNA encoding a cyclooxygenase-related
protein.10 Glucocorticoids play a major role
in the in vivo regulation of the cyclooxygenase 2 gene.11
Nonsteroidal anti-inflammatory drugs block prostaglandin biosynthesis by inhibitory
effects on cyclooxygenases 1 and 2.12-13
Thus, the mechanisms of actions of corticosteroids and nonsteroidal anti-inflammatory
drugs are different. Therefore, several time points for application of eyedrops
were chosen in the present study.
MATERIALS AND METHODS
ANIMALS
We used pigmented male rabbits (Japanese mongrel) that weighed 2.5 to
3.5 kg each. The animals were housed and treated according to the Association
for Research in Vision and Ophthalmology Resolution on Use of Animals in Research.
The study was approved by the Institutional Animal Care and Utilization Committee,
Toyama Medical and Pharmaceutical University, Toyama, Japan. One eye of each
animal was used for the experiment. Four to 8 eyes were used in each group.
CHEMICAL SOLUTIONS
We used the following anti-inflammatory and antiallergic agents, which
were purchased as ophthalmic solutions: betamethasone sodium phosphate (Shionogi
Pharmaceutical Co Ltd, Osaka, Japan); fluorometholone acetate, levocabastine
hydrocloride, and pemirolast potassium (Santen Inc, Napa, Calif); diclofenac
sodium (Wakamoto Pharmaceutical Co, Ltd, Tokyo, Japan); pranoprofen (Senju
Pharmaceutical Co, Ltd, Osaka); cromolyn sodium (cromoglicate sodium) (Fujisawa
Pharmaceutical Co, Ltd, Osaka); tranilast (Kissei Pharmaceutical Co, Ltd,
Nagano, Japan); and ibudilast (Senju Pharmaceutical Co, Ltd) (Table 1). The PGE2 (Funakoshi Chemicals, Tokyo) was dissolved
in 100% ethanol and stored at -70°C. Prostaglandin E2
solution was diluted in 5% ethanol with 0.9% sodium chloride (NaCl) just before
use.
|
|
|
|
Table 1. Anti-inflammatory and Antiallergic Ophthalmic Solutions
|
|
|
In 1 eye, 50 µL of eyedrops or placebo (0.9% NaCl) was topically
instilled. Instillation took place once or twice before PGE2 application.
The investigator who administered the eyedrops was masked to the contents.
TRANSCORNEAL DIFFUSION OF PGE2
For transcorneal diffusion, a glass cylinder (11 mm in diameter) was
attached to the cornea, as described by Hirata et al.1
Next, 600 µL of PGE2 solution containing the study drug at
a dose of 25 µg/mL, or 7.09 x 10 -2mmol/L, was
delivered into the cylinder and pipetted out 4 minutes later. The cylinder
was removed, and the corneal surface and conjunctival sac were rinsed with
20 mL of 0.9% NaCl. The eyes received 2 transcorneal applications of PGE2 at 1- or 2-week intervals (Figure
1). The eyes pretreated with anti-inflammatory or antiallergic agents
or placebo (0.9% NaCl) were used initially for PGE2-induced flare
elevation. After the interval, the same eyes received PGE2 application
only.
|
|
|
|
Figure 1. Two applications of prostaglandin
E2 (PGE2). The eyes received 2 transcorneal diffusions
of PGE2 at 1- or 2-week intervals. AUC indicates area under the
curve, a measurement of aqueous flare.
|
|
|
AQUEOUS FLARE MEASUREMENT
Aqueous flare was measured with a laser flare-cell meter (FC 1000; Kowa
Co, Ltd, Tokyo, Japan) according to the method described by Sawa et al.14 A laser flare-cell meter was used to measure intracameral
protein levels. Five measurements were taken at each time point to obtain
the mean value. The measurement was taken in the midportion of the anterior
chamber, an area measuring 0.075 mm3. Aqueous flare elevation was
expressed as the area under the curve (AUC) and inhibition was estimated by
the following equation:

The investigator (X.-Y.Z.) who measured flare intensity was masked to
the treatment.
STATISTICS
Statistical analysis was performed using the Scheffé multiple
comparisons procedure. A probability (P) value of
less than .05 was considered significant. Unless otherwise indicated, data
are expressed as mean ± SD.
RESULTS
No remarkable changes in the systemic condition were noted after the
transcorneal diffusion of PGE2 and the topical instillation of
anti-inflammatory or antiallergic agents. Double instillation (1 and 0.5 hour
before PGE2 application) of 0.1% betamethasone, 0.1% fluorometholone,
0.1% diclofenac, 0.1% pranoprofen, 2% cromolyn, 0.5% tranilast, 0.025% levocabastine,
0.1% pemirolast, and 0.01% ibudilast did not induce aqueous flare elevation.
After PGE2 was administered, aqueous flare increased, reached
its maximum (450-470 photon counts/ms) at 60 to 90 minutes, and then gradually
decreased and returned to baseline levels at 7 to 8 hours (Figure 2). When 0.1% betamethasone was topically instilled 4 and
2 hours before PGE2 application, aqueous flare elevated to 225
photon counts/ms at 60 minutes and then gradually decreased (Figure 2A). When 0.1% betamethasone was instilled 1 and 0.5 hour
before PGE2 application, aqueous flare elevated to 365 photon counts/ms
at 60 minutes and then gradually decreased (Figure 2B).
|
|
|
|
Figure 2. Changes in flare intensity after
transcorneal diffusion of prostaglandin E2 (PGE2) with
or without topical 2-time instillation of betamethasone phosphate. A, Double
instillations 4 and 2 hours, and B, 1 and 0.5 hour before PGE2
application. Transcorneal application of PGE2, 25 µg/mL or
7.09 x 10 -2mmol/L, occurred for 4 minutes (black arrow).
White arrows indicate topical instillation of 0.1% betamethasone phosphate.
|
|
|
The effects of double instillation of anti-inflammatory and antiallergic
eyedrops on aqueous flare elevation are shown in Table 2. Double instillations of 0.1% betamethasone and 0.1% fluorometholone
at 4 and 2 hours before PGE2 application inhibited 61% ±
11% and 46% ± 14%, respectively, of the flare elevation.
|
|
|
|
Table 2. Effects of Double Instillation of Eyedrops on PGE2-Induced
Aqueous Flare Elevation in Pigmented Rabbits*
|
|
|
Double instillations of 0.1% diclofenac and 0.1% pranoprofen at 4 and
2 hours before PGE2 application did not inhibit the flare elevation.
Double instillations of 0.1% betamethasone, 0.1% fluorometholone, 0.1% diclofenac,
and 0.1% pranoprofen at 1 and 0.5 hour before PGE2 application
inhibited 16% ± 10%,16% ± 6%, 24% ± 9%, and 23% ±
10%, respectively, of the flare elevation. Double instillations of 2% cromolyn,
0.5% tranilast, 0.025% levocabastine, 0.1% pemirolast, and 0.01% ibudilast
at 1 and 0.5 hour before PGE2 application did not inhibit flare
elevation.
Betamethasone needed several hours after topical instillation to exhibit
inhibition of flare elevation (Table 3).
When instilled 1 hour before PGE2 application, a single drop of
0.1% diclofenac inhibited flare elevation more strongly (23% ± 10%)
than did 0.1% betamethasone (12% ± 6%). When instilled 6 hours before
PGE2 application, a single drop of 0.1% diclofenac did not inhibit
flare elevation, but 0.1% betamethasone did (88% ± 10%).
|
|
|
|
Table 3. Effects of Single Instillation of Eyedrops on PGE2-Induced
Aqueous Flare Elevation in Pigmented Rabbits*
|
|
|
COMMENT
In the present study, 0.1% betamethasone and 0.1% fluorometholone instilled
4 and 2 hours before PGE2 application showed stronger inhibition
of flare elevation than those instilled 1 and 0.5 hour before PGE2
application. Single instillations of 0.1% betamethasone 6 hours before PGE2 application inhibited 88% of aqueous flare elevation. The peak of
prednisolone acetate concentration occurred 30 to 45 minutes after topical
instillation in humans and rabbits.15 Corticosteroids
might need several hours after administration to show action by inhibitory
effects on expression of the messenger RNAencoding cyclooxygenase-related
protein.10 Diclofenac and pranoprofen instilled
1 and 0.5 hour before PGE2 application inhibited flare elevation.
A single instillation of 0.1% diclofenac 1 hour before PGE2 application
inhibited 23% of aqueous flare elevation. Diclofenac directly inhibits cyclooxygenase.16 The different times from administration to inhibition
between betamethasone and diclofenac may be due to the dissimilar mechanisms
of action of these agents. Several authors have reported that nonsteroidal
anti-inflammatory drugs were more effective than corticosteroids in inhibiting
blood-aqueous barrier breakdown after cataract surgery.7, 17-19
However, the action of diclofenac was weaker than that of betamethasone in
the present study. A quantitative study of inhibitory effects on postsurgical
inflammation by these agents is needed. Some authors compared topical instillations
of corticosteroid and nonsteroidal anti-inflammatory drugs 1 hour before the
production of experimental uveitis and then at hourly intervals for 6 hours.20 We believe that further studies looking at different
dosing schedules could prove beneficial.
Antiallergic agents did not inhibit flare elevation. It is unlikely
that these agents affected disruption of the blood-aqueous barrier in rabbits.
Another study found PGE2-like activity in the aqueous humor
after paracentesis in rabbits.21 The PGE2 may be involved in traumatic iridocyclitis. The blood-aqueous barrier
in rabbits has unique sensitivity to prostaglandins.22
Therefore, the findings in the present study are not always identical to those
seen in humans. The exact mechanisms of inhibition by corticosteroids and
nonsteroidal anti-inflammatory drugs in rabbits and humans should be studied
further.
AUTHOR INFORMATION
Submitted for publication June 29, 2001; final revision received January
14, 2002; accepted March 20, 2002.
Corresponding author and reprints: Yoriko Hayasaka, MD, Department
of Ophthalmology, Toyama Medical and Pharmaceutical University, 2630 Sugitani,
Toyama 930-0194, Japan (e-mail: ophthal{at}ms.toyama-mpu.ac.jp).
From the Department of Ophthalmology, Toyama Medical and Pharmaceutical
University, Toyama, Japan.
REFERENCES
 |  |
1. Hirata H, Hiraki S, Kaji Y, Takeda N, Fukuo Y, Tachinami K. The effects of transcorneal administration of prostaglandin E2 on rabbit eyes. Nippon Ganka Gakkai Zasshi. 1994;98:927-934.
PUBMED
2. Numata-Watanabe K, Hirata H, Hiraki S, Hayasaka S. Decreased aqueous-flare reaction to repeated applications of prostaglandin
E2 to the cornea in pigmented rabbits. Ophthalmic Res. 1996;28:147-152.
ISI
| PUBMED
3. Watanabe K, Hayasaka S, Hiraki S, et al. Effects of topical clonidine on prostaglandin E2-induced
aqueous flare elevation in pigmented rabbits. Ophthalmic Res. 2000;32:210-214.
FULL TEXT
|
ISI
| PUBMED
4. Yanagisawa S, Hayasaka S, Zhang XY, Hayasaka Y, Nagaki Y, Kitagawa K. Effect of topical betaxolol on acute rise of aqueous flare induced
by prostaglandin E2 in pigmented rabbits. Jpn J Ophthalmol. 2001;45:669-671.
FULL TEXT
| PUBMED
5. Hayasaka Y, Hayasaka S, Zhang XY, Nagaki Y. Effects of topical antiglaucoma eye drops on prostaglandin E2induced aqueous flare elevation in pigmented rabbits. Invest Ophthalmol Vis Sci. 2002;43:1142-1145.
FREE FULL TEXT
6. Othenin-Girard P, Tritten JJ, Pittet N, Herbort CP. Dexamethasone versus diclofenac sodium eyedrops to treat inflammation
after cataract surgery. J Cataract Refract Surg. 1994;20:9-12.
ISI
| PUBMED
7. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid
macular edema after small incision cataract surgery: a multicentered prospective
trial. Jpn J Ophthalmol. 2000;44:58-67.
FULL TEXT
| PUBMED
8. Berdy GJ, Abelson MB. Antihistamines and mast cell stabilizers in allergic ocular disease. In: Albert DM, Jacobiec FA, eds. Principles and
Practice of Ophthalmology. Philadelphia, Pa: WB Saunders Co; 1994:1028-1042.
9. Abelson MB, Butrus S. Corticosteroids in ophthalmic practice. In: Albert DM, Jacobiec FA, eds. Principles and
Practice of Ophthalmology. Philadelphia, Pa: WB Saunders Co; 1994:1013-1022.
10. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related
protein. J Biol Chem. 1991;266:23261-23267.
FREE FULL TEXT
11. Masferrer JL, Reddy ST, Zweifel BS, et al. In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1
in peritoneal macrophages. J Pharmacol Exp Ther. 1994;270:1340-1344.
FREE FULL TEXT
12. To K, Abelson MB, Neufeld A. Nonsteroidal anti-inflammatory drugs. In: Albert DM, Jacobiec FA, eds. Principles and
Practice of Ophthalmology. Philadelphia, Pa: WB Saunders Co; 1994:1022-1027.
13. Battistini B, Botting R, Bakhle YS. COX-1 and COX-2: toward the development of more selective NSAIDs. Drug News Perspect. 1994;7:501-512.
14. Sawa M, Tsurimaki Y, Tsuru T, Shimizu H. New quantitative method to determine protein concentration and cell
number in aqueous in vivo. Jpn J Ophthalmol. 1988;32:132-142.
PUBMED
15. Leibowitz HM, Berrospi AR, Kupferman A, Restropo GV, Galvis V, Alvarez JA. Penetration of topically administered prednisolone acetate into the
human aqueous humor. Am J Ophthalmol. 1977;83:402-406.
ISI
| PUBMED
16. Noonan WD, Samples JR. Diclofenac sodium. J Toxicol Cutan Ocul Toxicol. 1993;12:265-272.
17. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inflammatory agents. Arch Ophthalmol. 1984;102:1453-1456.
ABSTRACT
18. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and
0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous
barrier. Arch Ophthalmol. 1988;106:480-483.
ABSTRACT
19. Kraff MC, Sanders DR, McGuigan L, Raanan MG. Inhibition of blood-aqueous humor barrier breakdown with diclofenac. Arch Ophthalmol. 1990;108:380-383.
ABSTRACT
20. Tilden ME, Boney RS, Goldenberg MM, Rosenbaum JT. The effects of topical S(+)ibuprofen on interleukin-1 induced
ocular inflammation in a rabbit model. J Ocul Pharmacol. 1990;6:131-135.
ISI
| PUBMED
21. Miller JD, Eakins KE, Atwal M. The release of PGE2-like activity into aqueous humor after
paracentesis and its prevention by aspirin. Invest Ophthalmol. 1973;12:939-942.
FREE FULL TEXT
22. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous
barrier function. Surv Ophthalmol. 1997;41(suppl 2):S69-S75.
|